Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30672649 | 1.00 | ENPP2 (0.34) | ENPP2RIPK1PLCG1GAALIPE | |
| SCHEMBL30761883 | 0.85 | SSTR4 (0.37) | ENPP2SSTR4 | |
| SCHEMBL5128448 | 0.85 | SSTR4 (0.37) | ENPP2SSTR4 | |
| SCHEMBL29489857 | 0.79 | ENPP2 (0.47) | ENPP2LIPETDP1APLNR | |
| SCHEMBL4794 | 0.79 | ENPP2 (0.47) | ENPP2LIPETDP1APLNR | |
| Water SCHEMBL29953222 | 0.77 | ENPP2 (0.45) | ENPP2LIPETDP1APLNR | |
| Water SCHEMBL1543573 | 0.77 | ENPP2 (0.45) | ENPP2LIPETDP1APLNR | |
| Hydrochloric Acid SCHEMBL29955441 | 0.77 | ENPP2 (0.45) | ENPP2LIPETDP1APLNR | |
| SCHEMBL27188178 | 0.76 | SLC13A5 (0.42) | GAAMEN1KMT2A | |
| SCHEMBL29514083 | 0.76 | ALDH1A1 (0.44) | GAAPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117447475-A | Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors | H.隆德贝克有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-111511742-B | Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11535611-B2 | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-12-27 | — | — | US | disclosed |
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20210009571-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-01-14 | — | — | US | disclosed |
| EP-3728250-A1 | PYRAZOLO[3,4-beta]PYRIDINES AND IMIDAZO[1,5-beta]PYRIDAZINES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2020-10-28 | — | — | EP | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| CN-111511742-A | Pyrazolo [3,4-b ] pyridines and imidazo [1,5-b ] pyridazines as PDE1 inhibitors | H.隆德贝克有限公司 | 2020-08-07 | — | — | CN | disclosed |
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9353091-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353091-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | ABBVIE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | ABBVIE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | ABBVIE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-8748443-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748443-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748443-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009571-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | PDE5A, PDE12, PDE3A | ENPP2 1528/4885RIPK1 3797/4885PLCG1 649/4885 |
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | ENPP2 3570/4885RIPK1 1518/4885PLCG1 2942/4885 |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ENPP2 1087/4885RIPK1 2146/4885PLCG1 3738/4885 |
| US-11535611-B2 | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors | PDE5A, PDE12, PDE3A | ENPP2 1528/4885RIPK1 3797/4885PLCG1 649/4885 |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | ENPP2 3570/4885RIPK1 1518/4885PLCG1 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.